id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-P-0471-0010,FDA,FDA-2009-P-0471,"FDA/CDER Response to Mark Antell, et al - Petition Partial Approval and Denial",Other,PPAD-Petition Partial Approval and Denial,2010-04-30T04:00:00Z,2010,4,2010-04-30T04:00:00Z,,2013-07-27T23:17:05Z,,0,0,0900006480ae178e
FDA-2009-P-0471-0009,FDA,FDA-2009-P-0471,"FDA/CDER Interim Response to Mark Antell, et al - Letter",Other,LET-Letter,2010-04-09T04:00:00Z,2010,4,2010-04-09T04:00:00Z,,2013-07-27T23:15:20Z,,0,0,0900006480ad44ba
FDA-2009-P-0471-0008,FDA,FDA-2009-P-0471,"Mark Antell, et al - Supplement",Other,SUP-Supplement,2010-02-01T05:00:00Z,2010,2,2010-02-01T05:00:00Z,,2013-08-11T04:37:00Z,,0,0,0900006480a6a34e